{"id":4391,"date":"2026-11-18T09:00:00","date_gmt":"2026-11-18T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4391"},"modified":"2026-11-18T21:45:31","modified_gmt":"2026-11-19T01:45:31","slug":"plasma-rna-signature-tracks-lymphoma-car-t-outcomes","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4391","title":{"rendered":"Plasma RNA Signature Tracks Lymphoma CAR T Outcomes"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Cornell_cfRNA_CAR_T_Technology_and_Modalities-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4412\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Cornell_cfRNA_CAR_T_Technology_and_Modalities-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Cornell_cfRNA_CAR_T_Technology_and_Modalities-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Cornell_cfRNA_CAR_T_Technology_and_Modalities-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Cornell_cfRNA_CAR_T_Technology_and_Modalities-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Cornell_cfRNA_CAR_T_Technology_and_Modalities.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Cornell University; Dana-Farber (academic)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (Cell Reports Medicine)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Plasma cell-free RNA biomarker<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Pretreatment cfRNA signature<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Lymph-node-like tumor microenvironment signature<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Large B-cell lymphoma (axi-cel CAR T)<\/p>\n<h4>Summary<\/h4>\n<p>A Cell Reports Medicine study published online November 18 associates pretreatment plasma cell-free RNA with later outcomes in 91 large B-cell lymphoma patients receiving axicabtagene ciloleucel across three institutional cohorts. A lymph-node-like tumor-microenvironment signature appeared in plasma of responders and was not reproduced in matched circulating mononuclear cells.<\/p>\n<p>The Cornell and Dana-Farber investigators assessed baseline plasma from three cohorts of 28, 28 and 35 patients. The earlier manuscript was posted as a non-peer-reviewed medRxiv preprint in March; the new evidence class is peer-reviewed journal publication. The group reports above-median signature scores associated with substantially lower progression risk, while cross-validated predictive discrimination was moderate. The article was announced November 18, separate from any future clinical implementation.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> cfRNA may expose tissue immune context through an ordinary blood draw and support risk-stratified CAR-T combinations or trial enrollment.<\/p>\n<p><strong>Interpretation B:<\/strong> the signal may encode tumor burden, selection, preprocessing or treatment-path differences rather than a causal immune niche. The three cohorts came from one center and one CAR-T product; apparent replication across batches is not external institutional validation. A median test AUC around 0.73 does not justify withholding a potentially curative therapy. Clinical value requires prespecified thresholds, comparison with LDH, PET, ctDNA and biopsy, robust sample handling, calibration and proof that a decision guided by the assay improves outcomes. Disease-specific RNA shedding and timing relative to bridging therapy may limit transferability.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Large B-cell lymphoma is an aggressive B-cell malignancy treated in relapse with CD19-directed autologous CAR-T such as axi-cel. Plasma cfRNA reflects RNA shed from tumors and surrounding tissue; this study uses it as a biomarker rather than a therapeutic agent.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Primary academic release and earlier underlying manuscript corroborate cohort size and methods; publisher DOI identifies the new peer-reviewed article.<\/li>\n<li>Missing: complete final paper access, independent multicenter validation and clinical decision study.<\/li>\n<li>Upgrade: locked classifier validated prospectively across products and centers.<\/li>\n<li>Downgrade: weakened signal after burden adjustment.<\/li>\n<li>Falsifier: no decision benefit despite analytic replication.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>Plasma cfRNA is a credible pretreatment biomarker hypothesis for CAR-T outcome, not a clinically qualified selection test.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: Moderate to High. Confidence in Interpretation: Low to Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Cell Reports Medicine study published online November 18 associates pretreatment plasma cell-free RNA with later outcomes in 91 large B-cell lymphoma patients receiving axicabtagene ciloleucel across three institutional cohorts. A lymph-node-like tumor-microenvironment signature&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4412,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1188,1530,1529],"class_list":["post-4391","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-axicabtagene-ciloleucel","tag-cell-free-rna","tag-cornell-university"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4391"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4391\/revisions"}],"predecessor-version":[{"id":4417,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4391\/revisions\/4417"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4412"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}